Purdue University

About: Purdue University is a education organization based out in West Lafayette, Indiana, United States. It is known for research contribution in the topics: Population & Context (language use). The organization has 73219 authors who have published 163563 publications receiving 5775236 citations. The organization is also known as: Purdue & Purdue-West Lafayette.

Working Memory Training Does Not Improve Performance on Measures of Intelligence or Other Measures of "Far Transfer": Evidence From a Meta-Analytic Review.

Abstract: It has been claimed that working memory training programs produce diverse beneficial effects. This article presents a meta-analysis of working memory training studies (with a pretest-posttest design and a control group) that have examined transfer to other measures (nonverbal ability, verbal ability, word decoding, reading comprehension, or arithmetic; 87 publications with 145 experimental comparisons). Immediately following training there were reliable improvements on measures of intermediate transfer (verbal and visuospatial working memory). For measures of far transfer (nonverbal ability, verbal ability, word decoding, reading comprehension, arithmetic) there was no convincing evidence of any reliable improvements when working memory training was compared with a treated control condition. Furthermore, mediation analyses indicated that across studies, the degree of improvement on working memory measures was not related to the magnitude of far-transfer effects found. Finally, analysis of publication bias shows that there is no evidential value from the studies of working memory training using treated controls. The authors conclude that working memory training programs appear to produce short-term, specific training effects that do not generalize to measures of “real-world” cognitive skills. These results seriously question the practical and theoretical importance of current computerized working memory programs as methods of training working memory skills.

Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography

Abstract: — An improved method for the measurement of catecholamines in brain parts has been developed, based on reverse-phase ion-pair chromatography. The new method offers the advantages of high efficiency microparticulate liquid chromatography packings and the flexibility of ion-pair chromatography. By this approach norepinephrine and dopamine (DA) have been measured in the hypothalamus and corpus striatum of the rat brain during various stages of development (15, 21, 30 days). Data are reported on the basis of the whole part and per weight of tissue. For the adult animals, the following concentrations (ng/g wet tissue) were observed for the hypothalamus: NE = 2261 ± 274, DA = 440 ± 103, and for the corpus striatum: DA = 11,888 ± 1840. The overall precision of the method was ±5.6% relative s.d. The absolute recovery was 60 ± 5% relative s.d. and was constant over the range of 1 ng to 1 μg of dopamine or norepinephrine per tissue sample. The relative retention behavior of 18 neurologically important catechol derivatives is reported for reverse-phase chromatography with octyl sulfate as the stationary phase modifier.

High-field quasiballistic transport in short carbon nanotubes.

Abstract: Single walled carbon nanotubes with Pd Ohmic contacts and lengths ranging from several microns down to 10 nm are investigated by electron transport experiments and theory. The mean-free path (MFP) for acoustic phonon scattering is estimated to be ${l}_{\mathrm{ap}}\ensuremath{\sim}300\text{ }\text{ }\mathrm{nm}$, and that for optical phonon scattering is ${l}_{\mathrm{op}}\ensuremath{\sim}15\text{ }\text{ }\mathrm{nm}$. Transport through very short ($\ensuremath{\sim}10\text{ }\text{ }\mathrm{nm}$) nanotubes is free of significant acoustic and optical phonon scattering and thus ballistic and quasiballistic at the low- and high-bias voltage limits, respectively. High currents of up to $70\text{ }\ensuremath{\mu}\mathrm{A}$ can flow through a short nanotube. Possible mechanisms for the eventual electrical breakdown of short nanotubes at high fields are discussed. The results presented here have important implications to high performance nanotube transistors and interconnects.

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

Abstract: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19)1. The development of a vaccine is likely to take at least 12–18 months, and the typical timeline for approval of a new antiviral therapeutic agent can exceed 10 years. Thus, repurposing of known drugs could substantially accelerate the deployment of new therapies for COVID-19. Here we profiled a library of drugs encompassing approximately 12,000 clinical-stage or Food and Drug Administration (FDA)-approved small molecules to identify candidate therapeutic drugs for COVID-19. We report the identification of 100 molecules that inhibit viral replication of SARS-CoV-2, including 21 drugs that exhibit dose–response relationships. Of these, thirteen were found to harbour effective concentrations commensurate with probable achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod2–4 and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and ONO 5334. Notably, MDL-28170, ONO 5334 and apilimod were found to antagonize viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, their known pharmacological and human safety profiles will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19. A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronavirus disease 2019 (COVID-19).